RPRoyalty Pharma RPRX · NASDAQ
$65.93 +1.71% (+$1.11)
- Market cap
- $29.4B
- Enterprise value
- $37.5B
- P/E
- 36.0x
- Forward P/E
- -
- PEG
- -
- P/S
- 11.6x
- P/FCF
- 9.9x
- EV/EBITDA
- 21.9x
- ROIC
- 8.1%
- Gross margin
- 89.4%
- Net margin
- 32.1%
- Dividend yield
- 1.40%
- Payout ratio
- 50.5%
- Net debt/EBITDA
- 4.7x
- Beta
- 0.41
- Free float
- 93.8%
About the company
Royalty Pharma plc is an international pharmaceutical company based in New York, USA, specializing in investments in royalty and licensing rights to pharmaceutical products. The company focuses on providing financial resources to research and development pharmaceutical companies in exchange for rights to profits from the sale of their drugs.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Pablo Legorreta
Employees
100
Headquarters
New York
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Earnings per share grew by 162% a year over the last 3 years.
- What to watch: Revenue grew by only 2.1% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 32 USD is left as net profit.
Financial health
Can it carry its debt?
- What to watch: Repaying its net debt would take 4.7 years of operating profit.
Capital and dividends
What does the company do with the money it earns?
- What speaks for it: It has raised its dividend 5 years in a row and pays out only 51% of profit.
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number